At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF) in Patient With Resectable Stage III-IV Squamous Cell Carcinoma of the Oropharynx
In Brief
A Phase 2 clinical trial evaluating cisplatin, docetaxel, and 2 other interventions for Head and Neck Cancer. Completed, enrolled 42 participants across 8 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with cetuximab may kill more tumor cells. PURPOSE: This phase II clinical trial is studying how well cetuximab given together with combination chemotherapy works in treating patients with stage III or stage IV oropharynx cancer that can be removed by surgery.
Study Details
Timeline
Interventions
75 mg/m², day 1. 3 cycles
75 mg/m² Day 1. 3 cycles
750 mg/m² day 1 to day 5. 3 cycles
400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.